cell lung cancer (NSCLC) unsuitable for radical therapy" (Abstract number
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time to time in the Company's ongoing quarterly and annual reporting.
Certain of the assumptions made in preparing forward-looking statements
include but are not limited to the following: that nimotuzumab will
continue to demonstrate a competitive safety profile in ongoing and future
clinical trials; that AeroLEF- will continue to generate positive efficacy
and safety data in future clinical trials; and that YM and its various
partners will complete their respective clinical trials within the
timelines communicated in this release. We undertake no
|SOURCE YM BioSciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved